Nama's AI scorecard currently rates Revolution Medicines Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does RVMD report earnings?

Revolution Medicines's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$1.29.

What is the RVMD price target?

The median analyst price target from 24 analysts is $260.00, with a range of $179.00 – $320.00.

Is RVMD Shariah compliant?

Nama's AAOIFI-style screen reads Revolution Medicines as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

Revolution Medicines (RVMD)

Healthcare · Biotechnology · NASDAQ

Revolution Medicines (RVMD) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $41.59B and a free-cash-flow yield of -2.5%. Nama's AI scorecard rates it Sell, 2.8 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 2.8/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Leading · +227.3% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-14.3%

How far the last close sits under the highest price of the past five years.

Market cap	$41.59B
Trailing P/E	—
Price / book	15.8
Price / sales	—
FCF yield	-2.5%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	-100.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

RVMD earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate -$1.29). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$1.90	-$2.38	+20.2%	$197.56M
Q2 2026	Aug 5, 2026	-$3.06	-$2.06	-48.5%	$0
Q1 2026	May 6, 2026	-$2.29	-$1.84	-24.5%	$0
Q4 2025	Feb 25, 2026	-$1.86	-$1.56	-19.2%	$0

RVMD analyst price target

Median target $260.00 from 24 analysts, ranging $179.00 – $320.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9
ROIV	Roivant Sciences	$28.08B	—

Explore live RVMD data on Nama Insights →

RVMD FAQ

Is RVMD a buy?: Nama's AI scorecard currently rates Revolution Medicines Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does RVMD report earnings?: Revolution Medicines's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$1.29.
What is the RVMD price target?: The median analyst price target from 24 analysts is $260.00, with a range of $179.00 – $320.00.
Is RVMD Shariah compliant?: Nama's AAOIFI-style screen reads Revolution Medicines as Can't Tell. A figure the screen needs is missing, so it can't tell.